Peripheral blood progenitors as a target for genetic correction of p47phox-deficient chronic granulomatous disease

S Sekhsaria, J I Gallin, G F Linton, R M Mallory, R C Mulligan, H L Malech, S Sekhsaria, J I Gallin, G F Linton, R M Mallory, R C Mulligan, H L Malech

Abstract

Peripheral blood contains hematopoietic progenitors (PBHPs), which can be harvested in clinically relevant amounts by apheresis. PBHPs have been used as a source of progenitors alternative to marrow for autologous transplantation following intensive chemotherapy. We have determined culture conditions for growth and differentiation of PBHPs to the mature myeloid phenotype, which in the present study are employed to demonstrate the functional correction of an inherited disorder of myeloid cells in retrovirus-transduced human primary hematopoietic progenitors. Patients with chronic granulomatous disease (CGD) suffer from recurrent life-threatening infections because blood phagocytes fail to produce microbicidal superoxide (O2-.). One-third of the cases of CGD result from defects in the gene encoding p47phox, a cytoplasmic oxidase component required for O2-. generation. In the present study, a replication-defective retrovirus encoding p47phox was used to transduce PBHPs from patients with p47phox-deficient CGD, which resulted in significant correction of O2-. generation when PBHPs were differentiated to mature neutrophils and monocytes. This study provides a model for use of PBHPs in development of gene therapy for diseases affecting bone marrow.

References

    1. Blood. 1992 Sep 15;80(6):1418-22
    1. Blood. 1992 Sep 1;80(5):1125-9
    1. J Clin Invest. 1993 Jan;91(1):201-7
    1. Exp Hematol. 1993 Apr;21(4):585-91
    1. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
    1. Science. 1971 Jan 22;171(3968):293-4
    1. J Immunol. 1984 Dec;133(6):3006-9
    1. J Biol Chem. 1985 Jul 15;260(14):8438-46
    1. J Clin Invest. 1985 Oct;76(4):1581-4
    1. J Immunol. 1986 Feb 1;136(3):860-6
    1. J Immunol. 1988 Apr 1;140(7):2334-9
    1. N Engl J Med. 1988 Jul 21;319(3):146-51
    1. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4874-8
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6460-4
    1. Science. 1988 Dec 2;242(4883):1298-301
    1. Science. 1989 Jul 28;245(4916):409-12
    1. N Engl J Med. 1989 Sep 7;321(10):647-52
    1. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7195-9
    1. Biochem J. 1989 Aug 15;262(1):373-5
    1. Exp Hematol. 1990 Feb;18(2):94-8
    1. JAMA. 1990 Mar 16;263(11):1533-7
    1. Biotechniques. 1989 Oct;7(9):980-2, 984-6, 989-90
    1. Science. 1990 May 11;248(4956):727-30
    1. Proc Natl Acad Sci U S A. 1990 May;87(10):3738-42
    1. Haematologica. 1990 Jan-Feb;75 Suppl 1:79-82
    1. J Infect Dis. 1990 Aug;162(2):523-8
    1. Eur J Cancer. 1990;26(5):562-4
    1. N Engl J Med. 1991 Feb 21;324(8):509-16
    1. Bone Marrow Transplant. 1991;7 Suppl 1:13-7
    1. J Biol Chem. 1991 Oct 15;266(29):19812-8
    1. Eur J Biochem. 1991 Dec 5;202(2):649-55
    1. Blood. 1992 Apr 1;79(7):1829-35
    1. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3790-4
    1. Science. 1992 Jun 5;256(5062):1459-62
    1. Blood. 1992 Jul 15;80(2):396-402
    1. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7640-4
    1. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10174-7

Source: PubMed

3
Předplatit